1901 Avenue of the Stars, 2nd Floor
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Founder: Robert Brooke, and Avtar Dhillon
Founder (Scientific): Brandon Zipp, PhD
CEO: Robert Brooke
FOLLOW VITALITY BIOPHARMA: